Adaptive Biotechnologies Corporation (ADPT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Adaptive Biotechnologies Corporation (ADPT) is down 1.5% since the beginning of the year. At $16 per share, ADPT is trading 23.0% below its 52-week high of $21. Investors who bought $1,000 worth of ADPT shares 5 years ago would now be looking at an investment worth $445.

Adaptive Biotechnologies Corporation (ADPT) has returned -1.54% so far this year and 60.87% over the past 12 months.

Based on dividend-adjusted daily data since Jun 27, 2019, ADPT's average daily return is +0.06%, while the average monthly return is +0.42%. At this rate, an investment would double in approximately 13.8 years.

Historically, 51% of months were positive and 49% were negative. The best month was Aug 2019 with a return of +31.9%, while the worst month was Apr 2022 at -40.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ADPT closed higher 49% of trading days. The best single day was May 2, 2025 with a return of +33.7%, while the worst single day was Nov 10, 2023 at -18.2%.

Adaptive Biotechnologies Corporation has an annualized alpha of -8.87%, beta of 1.57, and R2 of 0.17 versus S&P 500 Index. Calculated based on daily prices since June 28, 2019.

• This stock participated in 187.01% of S&P 500 Index downside but only 100.31% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.17 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ADPT ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Adaptive Biotechnologies Corporation (ADPT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Adaptive Biotechnologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adaptive Biotechnologies Corporation was 96.55%, occurring on Apr 18, 2024. The portfolio has not yet recovered.

The current Adaptive Biotechnologies Corporation drawdown is 76.40%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Adaptive Biotechnologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Adaptive Biotechnologies Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.